ReviewEClinicalMedicine2024
GLP-1 single, dual, and triple receptor agonists for treating type 2 diabetes and obesity: a narrative review.
Review in EClinicalMedicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 109 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
109 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Injection-site and dermatologic reactions associated with glucagon-like peptide-1 receptor agonists: Insights from meta-analysis of randomised controlled trials and real-world evidence.Diabetes, obesity & metabolism · 2026Pooled it
- New Perspectives in Modulating the Entero-Insular Axis in Pediatric Obesity.International journal of molecular sciences · 2025Pooled it
- Comparative effectiveness of semaglutideFrontiers in pharmacology · 2025Pooled it
- Weekly Subcutaneous VK2735, a GIP/GLP-1 Receptor Dual Agonist, for Weight Management: Phase 2, Randomized, 13-Week VENTURE Study.Obesity (Silver Spring, Md.) · 2026Trial
- Dermatologic outcomes associated with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a large-scale target trial emulation.Frontiers in endocrinology · 2026Trial
- Article
- Clinical Characterization of Enzyme and Transporter Precipitants to Evaluate Drug-Drug Interactions for Orforglipron, a Small Molecule Glucagon-Like Peptide-1 Receptor Agonist.Clinical pharmacology and therapeutics · 2026Article
- Exit Interviews Examining Patient Experiences with Tirzepatide and Dulaglutide for Treatment of Type 2 Diabetes in the SURPASS-CVOT Trial.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2026Article
- Efficacy and Safety of Tirzepatide Versus Dulaglutide in Type 2 Diabetes With or Without Established Atherosclerotic Cardiovascular Disease: A Network Meta-Analysis of Randomized Clinical Trials.Endocrinology, diabetes & metabolism · 2026Review
- Tirzepatide for Excess Weight in Adults With Type 1 Diabetes Using MiniMed 780G.Diabetes, obesity & metabolism · 2026Article
- The Effects of Incretin Mimetic Therapies on Muscle and Bone Health in Older Adults: A Narrative Review.Obesity (Silver Spring, Md.) · 2026Review
- Tirzepatide Is Associated With Improved Metabolic Outcomes in People With Type 1 Diabetes and Overweight or Obesity: A Retrospective Cohort Study.Diabetes, obesity & metabolism · 2026Article
- Article
- Metabolic effects of GLP-1 receptor agonists in rheumatology patients and inflammatory outcomes: a single-centre retrospective cohort.RMD open · 2026Article
- Review
- Multicomponent Stapling of Glucagon-Like Peptide-1 Enables Receptor-Guided PROTAC Delivery.Angewandte Chemie (International ed. in English) · 2026Article
- GLP-1 Receptor Agonists in Obstructive Sleep Apnea: A Translational Perspective on Mechanisms and Clinical Implications.International journal of molecular sciences · 2026Review
- Sulforaphane and Broccoli-Derived Preparations in Obesity and Obesity-Related Metabolic Dysfunction: Mechanistic Insights, Preclinical Evidence, and Clinical Perspectives.Pharmaceuticals (Basel, Switzerland) · 2026Review
- External Validation of SELECT Trial-Derived Cardiovascular Risk Equations in a UK Population with Overweight or Obesity and Established Cardiovascular Disease Without Diabetes.PharmacoEconomics · 2026Article
- Psoriatic arthritis and obesity: a review of clinical burden and considerations for comprehensive care.RMD open · 2026Review
49 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Obesity and type 2 diabetes mellitus (T2DM) present major global health challenges, with an increasing prevalence worldwide. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have emerged as a pivotal treatment option for both conditions, demonstrating efficacy in blood glucose management, weight reduction, cardiovascular disease prevention, and kidney health improvement. GLP-1, an incretin hormone, plays a crucial role in glucose metabolism and appetite regulation, influencing insulin secretion, insulin sensitivity, and gastric emptying. The therapeutic use of GLP-1RAs has evolved significantly, offering various formulations that provide different efficacy, routes of administration, and flexibility in dosing. These agents reduce HbA1c levels, facilitate weight loss, and exhibit cardiovascular protective effects, making them an integral component of T2DM and obesity management. This review will discuss the currently approved medication for T2DM and obesity, and will also highlight the advent of novel agents which are dual and triple hormonal agonists which represent the future direction of incretin-based therapy. Funding: National Institutes of HealthNIDDKU24 DK132733 (FCS), UE5 DK137285 (FCS), and P30 DK040561 (FCS).
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.